Seek Returns logo

ABBV vs. TEM: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ABBV and TEM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolABBVTEM
Company NameAbbVie Inc.Tempus AI, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization366.65 billion USD13.19 billion USD
ExchangeNYSENasdaqGS
Listing DateJanuary 2, 2013June 14, 2024
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of ABBV and TEM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. TEM: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolABBVTEM
5-Day Price Return0.66%3.86%
13-Week Price Return13.70%28.10%
26-Week Price Return5.17%-11.45%
52-Week Price Return5.69%17.62%
Month-to-Date Return9.80%34.12%
Year-to-Date Return16.80%124.82%
10-Day Avg. Volume4.52M15.07M
3-Month Avg. Volume6.27M12.32M
3-Month Volatility19.40%79.97%
Beta0.493.06

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

ABBV’s Return on Equity of 95.59% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

TEM

-107.12%

Life Sciences Tools & Services Industry

Max
19.96%
Q3
11.55%
Median
6.22%
Q1
3.86%
Min
-6.95%

TEM has a negative Return on Equity of -107.12%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ABBV vs. TEM: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

TEM

-20.98%

Life Sciences Tools & Services Industry

Max
27.28%
Q3
16.17%
Median
7.24%
Q1
3.00%
Min
-3.05%

TEM has a negative Net Profit Margin of -20.98%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ABBV vs. TEM: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

TEM

-24.66%

Life Sciences Tools & Services Industry

Max
33.15%
Q3
19.34%
Median
13.02%
Q1
8.05%
Min
-4.38%

TEM has a negative Operating Profit Margin of -24.66%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ABBV vs. TEM: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Profitability at a Glance

SymbolABBVTEM
Return on Equity (TTM)95.59%-107.12%
Return on Assets (TTM)2.73%-15.77%
Net Profit Margin (TTM)6.45%-20.98%
Operating Profit Margin (TTM)18.80%-24.66%
Gross Profit Margin (TTM)70.93%60.73%

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

ABBV’s Current Ratio of 0.74 is notably low, falling beneath the typical range for the Biotechnology industry. This suggests a heightened liquidity risk and could indicate potential challenges in meeting its short-term obligations.

TEM

1.54

Life Sciences Tools & Services Industry

Max
4.76
Q3
2.77
Median
1.85
Q1
1.40
Min
0.43

TEM’s Current Ratio of 1.54 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.

ABBV vs. TEM: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

TEM

2.58

Life Sciences Tools & Services Industry

Max
1.75
Q3
0.83
Median
0.41
Q1
0.18
Min
0.00

With a Debt-to-Equity Ratio of 2.58, TEM operates with exceptionally high leverage compared to the Life Sciences Tools & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

ABBV vs. TEM: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

TEM

-14.08

Life Sciences Tools & Services Industry

Max
29.61
Q3
23.24
Median
6.07
Q1
2.18
Min
-14.08

TEM has a negative Interest Coverage Ratio of -14.08. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ABBV vs. TEM: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Financial Strength at a Glance

SymbolABBVTEM
Current Ratio (MRQ)0.741.54
Quick Ratio (MRQ)0.481.34
Debt-to-Equity Ratio (MRQ)49.222.58
Interest Coverage Ratio (TTM)2.70-14.08

Growth

Revenue Growth

ABBV vs. TEM: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. TEM: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

3.11%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ABBV’s Dividend Yield of 3.11% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

TEM

0.00%

Life Sciences Tools & Services Industry

Max
1.80%
Q3
0.78%
Median
0.37%
Q1
0.00%
Min
0.00%

TEM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ABBV vs. TEM: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

TEM

0.00%

Life Sciences Tools & Services Industry

Max
156.00%
Q3
65.73%
Median
23.81%
Q1
0.00%
Min
0.00%

TEM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ABBV vs. TEM: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Dividend at a Glance

SymbolABBVTEM
Dividend Yield (TTM)3.11%0.00%
Dividend Payout Ratio (TTM)226.84%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

96.80

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

At 96.80, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

TEM

--

Life Sciences Tools & Services Industry

Max
117.96
Q3
65.59
Median
37.26
Q1
27.51
Min
1.73

P/E Ratio data for TEM is currently unavailable.

ABBV vs. TEM: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

6.24

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

ABBV’s P/S Ratio of 6.24 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

TEM

13.37

Life Sciences Tools & Services Industry

Max
12.46
Q3
6.70
Median
4.24
Q1
2.68
Min
0.73

With a P/S Ratio of 13.37, TEM trades at a valuation that eclipses even the highest in the Life Sciences Tools & Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

ABBV vs. TEM: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

TEM

35.53

Life Sciences Tools & Services Industry

Max
7.99
Q3
4.69
Median
3.30
Q1
1.88
Min
1.02

At 35.53, TEM’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

ABBV vs. TEM: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Valuation at a Glance

SymbolABBVTEM
Price-to-Earnings Ratio (TTM)96.80--
Price-to-Sales Ratio (TTM)6.2413.37
Price-to-Book Ratio (MRQ)261.0135.53
Price-to-Free Cash Flow Ratio (TTM)19.97--